eFFECTOR Therapeutics Lands $45,000,000 Series A Funding

  • Feed Type
  • Date
    5/21/2013
  • Company Name
    eFFECTOR Therapeutics
  • Mailing Address
    11180 Roselle Street San Diego, CA 92121
  • Company Description
    eFFECTOR Therapeutics is pioneering a new class of small molecule drugs that act by selectively regulating translation, also known as protein synthesis. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention.
  • Website
    http://www.effector.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $45,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The funds will support multiple discovery programs and enable acquisition of tumor response data in patients for a lead drug candidate.
  • M&A Terms
  • Venture Investor
    U.S. Venture Partners
  • Venture Investor
    Abingworth Management
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    SR One
  • Venture Investor
    Astellas Venture Capital
  • Venture Investor
    Osage Ventures
  • Venture Investor
    Mission Bay Capital

By posting a comment, you agree to our terms and conditions.